PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Cortes, J. [1 ]
O'Connell, A. [2 ]
Shaik, M. N. [3 ]
Cesari, R. [4 ]
Abbattista, A. [4 ]
Woolfson, A. [5 ]
Pollyea, D. [6 ]
Savona, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Pfizer Oncol, Collegeville, PA USA
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Milan, Italy
[5] Pfizer Oncol, New York, NY USA
[6] Univ Colorado, Ctr Canc, Aurora, CO USA
[7] Tennessee Oncol, Nashville, TN USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P179
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [41] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Hellmann, Andrzej
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Pollyea, Daniel A.
    DesJardins, Pierre
    Ottmann, Oliver
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    LEUKEMIA, 2019, 33 (02) : 379 - 389
  • [42] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Amrein, Philip C.
    Attar, Eyal C.
    Fathi, Amir Tahmasb
    McAfee, Steven L.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Foster, Julia
    Stone, Richard M.
    Neuberg, Donna S.
    Ballen, Karen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [44] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [45] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
    Vigil, Carlos
    Jahan, Nusrat
    Paun, Oana
    Weis, Jennifer
    Heckman, Kevin
    Silverman, Margarida
    Carter, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S297 - S297
  • [46] Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality
    Walter, Roland B.
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Becker, Pamela S.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Othus, Megan
    Louie, Arthur C.
    Estey, Elihu H.
    BLOOD, 2014, 124 (21)
  • [47] A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Orlowski, Kaysey F.
    Scott, Bart L.
    Smith, Heather A.
    Becker, Pamela S.
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Perdue, Andrea M.
    Chen, Tara L.
    Buckley, Sarah A.
    Erba, Harry P.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2016, 128 (22)
  • [48] Final update of phase I-II study of the farnesyltransferase inhibitor tipifarnib in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan
    Koller, Charles A.
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 136A - 136A
  • [49] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Berdel, Andrew F.
    Koch, Raphael
    Gerss, Joachim
    Hentrich, Marcus
    Peceny, Rudolf
    Bartscht, Tobias
    Steffen, Bjoern
    Bischoff, Marina
    Spiekermann, Karsten
    Angenendt, Linus
    Mikesch, Jan-Henrik
    Kewitz, Tobias
    Butterfass-Bahloul, Trude
    Serve, Hubert
    Lenz, Georg
    Berdel, Wolfgang E.
    Krug, Utz
    Schliemann, Christoph
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 63 - 72
  • [50] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Andrew F. Berdel
    Raphael Koch
    Joachim Gerss
    Marcus Hentrich
    Rudolf Peceny
    Tobias Bartscht
    Björn Steffen
    Marina Bischoff
    Karsten Spiekermann
    Linus Angenendt
    Jan-Henrik Mikesch
    Tobias Kewitz
    Trude Butterfass-Bahloul
    Hubert Serve
    Georg Lenz
    Wolfgang E. Berdel
    Utz Krug
    Christoph Schliemann
    Annals of Hematology, 2023, 102 : 63 - 72
12345